FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310045802> ?p ?o ?g. }

• W4310045802 abstract "Abstract Background Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC. However, despite a response rate (RR) for approximately half of patients receiving standard chemotherapy, durable responses are rare (median progression-free progression (PFS) around 8 months). Recently, immune checkpoint inhibitors (ICI) have emerged as new therapeutic options. Among them, Avelumab, an anti-PD-L1 antibody, was assessed in maintenance treatment, demonstrating an overall survival improvement in the JAVELIN Bladder-100 phase III trial. These findings led to its approval as first line maintenance therapy for patients with locally advanced or metastatic UC who have not progressed on prior platinum-containing chemotherapy. However, disease progression as best response was noticed for 37% of patients under Avelumab as maintenance treatment. UC has targetable genomic alterations, including DNA damage repair (DDR) alterations. DDR deficiency is known to major sensitivity to both platinum-based chemotherapy and PD-1/PD-L1 blockade and the combination of ICI and PARP inhibitors showed promising results. It therefore warrants to assess the interest of combining ICI plus PARP inhibitors as maintenance treatment in UC patients. Methods The TALASUR trial is a single-arm multicenter phase 2 study aiming to assess the antitumor activity of the combination of Avelumab with Talazoparib among patients with locally advanced/metastatic UC in maintenance therapy after platinum-based chemotherapy. The primary objective is to determine the efficacy of the combination, assessed through PFS. Secondary objectives are as follows: safety profile of the association, objective response, duration of tumoral response, disease control rate, time to subsequent therapy, quality of life. A blood and tumor collections will be also constituted. Patient will receive the combination therapy of daily oral Talazoparib (1 mg/day) and intra-venous Avelumab 800 mg on days 1 and 15, in a 28-day cycle. Fifty patients will be enrolled. Discussion Talazoparib with Avelumab combination may have additive activity when administrated jointly. We hypothesize that combination will increase the antitumor activity in UC first line maintenance setting with an acceptable safety profile. Trial registration NCT04678362, registered December 21, 2020. Protocol version: Version 1.3 dated from 2020 09 11." @default.
• W4310045802 created "2022-11-30" @default.
• W4310045802 creator A5003798935 @default.
• W4310045802 creator A5008268754 @default.
• W4310045802 creator A5009640398 @default.
• W4310045802 creator A5011949577 @default.
• W4310045802 creator A5015165342 @default.
• W4310045802 creator A5016416039 @default.
• W4310045802 creator A5016517519 @default.
• W4310045802 creator A5023854119 @default.
• W4310045802 creator A5028829159 @default.
• W4310045802 creator A5031850292 @default.
• W4310045802 creator A5040394407 @default.
• W4310045802 creator A5042461515 @default.
• W4310045802 creator A5057264839 @default.
• W4310045802 creator A5071787067 @default.
• W4310045802 date "2022-11-24" @default.
• W4310045802 modified "2023-10-15" @default.
• W4310045802 title "TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma" @default.
• W4310045802 cites W2068523052 @default.
• W4310045802 cites W2581231749 @default.
• W4310045802 cites W2592941899 @default.
• W4310045802 cites W2891749509 @default.
• W4310045802 cites W2902946687 @default.
• W4310045802 cites W2921480061 @default.
• W4310045802 cites W2961496023 @default.
• W4310045802 cites W2962822814 @default.
• W4310045802 cites W2995672471 @default.
• W4310045802 cites W3016461381 @default.
• W4310045802 cites W3023288864 @default.
• W4310045802 cites W3034529377 @default.
• W4310045802 cites W3069915980 @default.
• W4310045802 cites W3080421257 @default.
• W4310045802 cites W3087464965 @default.
• W4310045802 cites W3088003217 @default.
• W4310045802 cites W3155705538 @default.
• W4310045802 cites W3158712737 @default.
• W4310045802 cites W3164048465 @default.
• W4310045802 cites W4200128746 @default.
• W4310045802 cites W4212895261 @default.
• W4310045802 cites W4213209893 @default.
• W4310045802 cites W4290879671 @default.
• W4310045802 doi "https://doi.org/10.1186/s12885-022-10216-z" @default.
• W4310045802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36434554" @default.
• W4310045802 hasPublicationYear "2022" @default.
• W4310045802 type Work @default.
• W4310045802 citedByCount "2" @default.
• W4310045802 countsByYear W43100458022023 @default.
• W4310045802 crossrefType "journal-article" @default.
• W4310045802 hasAuthorship W4310045802A5003798935 @default.
• W4310045802 hasAuthorship W4310045802A5008268754 @default.
• W4310045802 hasAuthorship W4310045802A5009640398 @default.
• W4310045802 hasAuthorship W4310045802A5011949577 @default.
• W4310045802 hasAuthorship W4310045802A5015165342 @default.
• W4310045802 hasAuthorship W4310045802A5016416039 @default.
• W4310045802 hasAuthorship W4310045802A5016517519 @default.
• W4310045802 hasAuthorship W4310045802A5023854119 @default.
• W4310045802 hasAuthorship W4310045802A5028829159 @default.
• W4310045802 hasAuthorship W4310045802A5031850292 @default.
• W4310045802 hasAuthorship W4310045802A5040394407 @default.
• W4310045802 hasAuthorship W4310045802A5042461515 @default.
• W4310045802 hasAuthorship W4310045802A5057264839 @default.
• W4310045802 hasAuthorship W4310045802A5071787067 @default.
• W4310045802 hasBestOaLocation W43100458021 @default.
• W4310045802 hasConcept C121608353 @default.
• W4310045802 hasConcept C126322002 @default.
• W4310045802 hasConcept C143998085 @default.
• W4310045802 hasConcept C2776694085 @default.
• W4310045802 hasConcept C2777381376 @default.
• W4310045802 hasConcept C2777701055 @default.
• W4310045802 hasConcept C2777742743 @default.
• W4310045802 hasConcept C2778283404 @default.
• W4310045802 hasConcept C2780057760 @default.
• W4310045802 hasConcept C2780140570 @default.
• W4310045802 hasConcept C2780352672 @default.
• W4310045802 hasConcept C2780739268 @default.
• W4310045802 hasConcept C2911057145 @default.
• W4310045802 hasConcept C3019882237 @default.
• W4310045802 hasConcept C71924100 @default.
• W4310045802 hasConceptScore W4310045802C121608353 @default.
• W4310045802 hasConceptScore W4310045802C126322002 @default.
• W4310045802 hasConceptScore W4310045802C143998085 @default.
• W4310045802 hasConceptScore W4310045802C2776694085 @default.
• W4310045802 hasConceptScore W4310045802C2777381376 @default.
• W4310045802 hasConceptScore W4310045802C2777701055 @default.
• W4310045802 hasConceptScore W4310045802C2777742743 @default.
• W4310045802 hasConceptScore W4310045802C2778283404 @default.
• W4310045802 hasConceptScore W4310045802C2780057760 @default.
• W4310045802 hasConceptScore W4310045802C2780140570 @default.
• W4310045802 hasConceptScore W4310045802C2780352672 @default.
• W4310045802 hasConceptScore W4310045802C2780739268 @default.
• W4310045802 hasConceptScore W4310045802C2911057145 @default.
• W4310045802 hasConceptScore W4310045802C3019882237 @default.
• W4310045802 hasConceptScore W4310045802C71924100 @default.
• W4310045802 hasIssue "1" @default.
• W4310045802 hasLocation W43100458021 @default.
• W4310045802 hasLocation W43100458022 @default.
• W4310045802 hasLocation W43100458023 @default.
• W4310045802 hasLocation W43100458024 @default.
• W4310045802 hasOpenAccess W4310045802 @default.

• next